Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemay005 in healthy Caucasian volunteers
NCT05941247Phase 1Completed
- Sponsor
- Hemay Pharmaceutical Technology
- Start
- Jul 2023
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mufemilast in Behçet's disease (BD), sponsored by Hemay Pharmaceutical Technology. Primary endpoints: Number of participants with Adverse Events, Number of participants with abnormal laboratory tests results and 2 more. Started Jul 2023; status: completed.
02
Drugs
mufemilast
03
Conditions
Behçet's disease (BD)
Beyond the preview
Go deeper on NCT05941247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05941247.